Literature DB >> 20944793

Can radiotherapy be a viable salvage treatment option for the relapsed seminoma confined to the infra-diaphragm region recurring after primary chemotherapy for bulky stage II seminoma?

Richard Choo1, Fernando Quevedo, Christopher S Choo, Michael Blute.   

Abstract

There has been a paucity of research describing a potential role of radiotherapy as salvage treatment for recurrent seminoma following primary chemotherapy for bulky stage IIC seminoma. We report a case of a bulky stage IIC seminoma relapsed in the pelvis after primary chemotherapy and surgery for post-chemotherapy residual mass, which was subsequently salvaged with radiotherapy. The patient has remained free of relapse at 3.7 years post-salvage radiotherapy. This case demonstrates that radiotherapy can be a salvage therapeutic option for recurrent seminoma following primary chemotherapy for bulky stage IIC seminoma, provided that the recurrent tumour is confined to a limited area of the infradiaphragmatic region. There is a need for further study to examine the potential role of radiotherapy as a salvage therapeutic tool for post-chemotherapy recurrent seminoma.

Entities:  

Year:  2010        PMID: 20944793      PMCID: PMC2950770          DOI: 10.5489/cuaj.937

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  5 in total

1.  NCCN clinical practice guidelines in oncology: testicular cancer.

Authors:  Robert J Motzer; Neeraj Agarwal; Clair Beard; Graeme B Bolger; Barry Boston; Michael A Carducci; Toni K Choueiri; Robert A Figlin; Mayer Fishman; Steven L Hancock; Gary R Hudes; Eric Jonasch; Anne Kessinger; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Kim A Margolin; M Dror Michaelson; Thomas Olencki; Roberto Pili; Bruce G Redman; Cary N Robertson; Lawrence H Schwartz; Joel Sheinfeld; Jue Wang
Journal:  J Natl Compr Canc Netw       Date:  2009-06       Impact factor: 11.908

2.  Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party.

Authors:  G M Duchesne; S P Stenning; N Aass; G M Mead; S D Fosså; R T Oliver; A Horwich; G Read; I T Roberts; G Rustin; M H Cullen; S B Kaye; S J Harland; P A Cook
Journal:  Eur J Cancer       Date:  1997-05       Impact factor: 9.162

Review 3.  Surgery for a post-chemotherapy residual mass in seminoma.

Authors:  H W Herr; J Sheinfeld; H S Puc; R Heelan; D F Bajorin; P Mencel; G J Bosl; R J Motzer
Journal:  J Urol       Date:  1997-03       Impact factor: 7.450

4.  Advanced seminoma--treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients.

Authors:  Dany Gholam; Karim Fizazi; Marie-Jose Terrier-Lacombe; Pascale Jan; Stephane Culine; Christine Theodore
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

5.  Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center.

Authors:  H S Puc; R Heelan; M Mazumdar; H Herr; J Scheinfeld; V Vlamis; D F Bajorin; G J Bosl; P Mencel; R J Motzer
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

  5 in total
  2 in total

Review 1.  Positive FDG-PET/CT scans of a residual seminoma after chemotherapy and radiotherapy: case report and review of the literature.

Authors:  Mehmet Asim Bilen; Houssam Hariri; Chady Leon; Charles C Guo; Deborah A Kuban; Louis L Pisters; Shi-Ming Tu
Journal:  Clin Genitourin Cancer       Date:  2014-02-28       Impact factor: 2.872

Review 2.  Contemporary management of stage I and II seminoma.

Authors:  Peter Chung; Padraig Warde
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.